$0.29 per basic and $0.30 diluted share for the third quarter of 2006
-- As of September 30, 2007, Emisphere had $21.4 million in cash and
Corporate and Product Developments
Emisphere has two Phase III products based on the compound salmon calcitonin in partnership with Novartis Pharma AG and its development partner, Nordic Bioscience:
-- One product relates to the prevention of osteoporosis and the other
product relates to the prevention of osteoarthritis
-- Osteoarthritis product has the potential to be the first disease-
modifying drug that halts progression of the illness rather than
-- Both products use Emisphere's eligen(R) delivery technology to provide
salmon calcitonin for the first time as a convenient oral medication
Emisphere has three products in Phase II:
-- Development of recombinant human growth hormone ("rhGH") in
collaboration with Novartis Pharma AG
-- Continuing the development of oral heparin; discussions with the US
Food and Drug Administration ("FDA") established a pathway for
registration to proceed into complete Phase III for the use of oral
heparin in the prevention of deep-vein thrombosis following elective
total hip replacement. Emisphere is in current discussions with a
potential partner to complete the development of oral heparin in a
collaborative arrangement. Two chronic toxicology studies have been
initiated for the heparin carrier.
-- Continuing clinical development of oral insulin; insulin/glucose clamp
and oral glucose challenge studies testing a new formulation are being
planned over a three month period beginning early next year.
Collaborative partnerships will then be investigated.
Emisphere has five products in Phase I:
-- An Investigational New Drug application ("IND")
|SOURCE Emisphere Technologies, Inc.|
Copyright©2007 PR Newswire.
All rights reserved